secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0001193125-25-031973
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa licenses LockBody platform to Genmab; $15M upfront, up to $230M per product milestones
--------------------------------------------------------------------------------

- Upfront payment of $15M from Genmab; option fees up to $15M for up to three undisclosed targets.
- Eligible for ~$230M in development, regulatory, and sales milestones per product plus tiered mid-single-digit royalties.
- Genmab to lead all R&D; may combine LockBody technology with Genmab's proprietary antibodies.
- LockBody platform enables conditional activation of cell killing in diseased tissue to improve therapeutic index.
- Multi-year research period; Genmab can terminate for convenience or on a target-by-target basis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312525031973/0001193125-25-031973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312525031973/d894992d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-031973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer